Clinical Trial Update: Bevacizumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER-2/NEU [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating bevacizumab in metastatic breast cancer that overexpresses HER-2/neu was terminated, and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Breast Carcinoma, Recurrent Breast Carcinoma | Phase 3 | Status: TERMINATED | Results posted: 2016-11-29